Trial · NCT07886710
A Randomized, Double-Blind, Placebo-Controlled Phase Ib Study of Multiple Ascending Doses of EB070 Injection in Adults With Moderate-to-Severe Asthma
NCT07886710, Phase 1, Not yet recruiting, Biotech Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Randomized, Double-Blind, Placebo-Controlled Phase Ib Study of Multiple Ascending Doses of EB070 Injection in Adults With Moderate-to-Severe Asthma. Trials, record NCT07886710. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886710
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Phase Ib Study of Multiple Ascending Doses of EB070 Injection in Adults With Moderate-to-Severe Asthma
- NCT number
- NCT07886710
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Biotech Pharmaceutical Co., Ltd.
- Conditions
- Asthma
- Interventions
- EB070
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | AEs | From the Start of Dosing Through Week 32 | including Adverse events defined by CTCAE 6.0(Common Terminology Criteria for Adverse Events version 6.0) |
| Secondary | Tss_max | From Week 1 to Week 32 | The time required to reach the maximum concentration of EB070 in the bloodstream after administration at steady state. |
| Secondary | Css_max | From Week 1 to Week 32 | The maximum concentration of EB070 in the bloodstream during a dosing interval at steady state. |
| Secondary | Css_min | From Week 1 to Week 32 | The minimum concentration of EB070 in the bloodstream during a dosing interval at steady state. |
| Secondary | AUCss 0-t | From week 1 to week 32 | The area under the concentration-time curve of EB070 from the start to the last measurable concentration during a dosing interval at steady state. |
| Secondary | AUCss 0-∞ | From week 1 to week 32 | The area under the concentration-time curve of EB070 from the start of a dosing interval to infinity at steady state. |
| Secondary | RAUC | From week 1 to week 32 | The ratio of EB070 exposure after repeated dosing to that after a single dose. |
| Secondary | RCmax | From week 1 to week 32 | The ratio of the maximum EB070 concentration after repeated dosing to that after a single dose. |
| Secondary | CL/Fss | From week 1 to week 32 | The apparent clearance of EB070 from the bloodstream at steady state. |
| Secondary | Vz/Fss | From week 1 to week 32 | The apparent volume of distribution of EB070 at steady state. |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886710
GET https://conductscience.org/api/trials/v1/NCT07886710/registered?page=2